Medicare GLP-1 Coverage Drives 700,000 New Senior Users, Lilly Says
Eli Lilly's CEO says 700,000 seniors have begun GLP-1 therapy since Medicare coverage launched in July, with 70% choosing Lilly products.
Eli Lilly's chief executive reported that approximately 700,000 Medicare-eligible seniors have initiated GLP-1 medications since the federal program began covering the class of drugs in July, with roughly 70% of those patients turning to Lilly's own treatments, according to remarks from the company's top executive.
The figures offer the clearest picture yet of how the Medicare coverage expansion is reshaping access to GLP-1 therapies — a category of drugs that has surged in demand for the treatment of diabetes and obesity. Prior to the coverage change, out-of-pocket costs placed the medications out of reach for many older Americans on fixed incomes.
Read more Clean Harbors Takes On $600M in Debt to Fund Acquisition Push →
Lilly's dominant share of the new Medicare patient base underscores the competitive advantage the Indianapolis-based drugmaker holds in the GLP-1 market, where it competes primarily against Danish pharmaceutical giant Novo Nordisk. The 70% figure suggests Lilly's portfolio has captured a disproportionately large slice of first-time senior users entering the market through the federal benefit.
The metrics also signal that government-backed coverage can act as a powerful demand catalyst in the pharmaceutical sector. Analysts have closely watched Medicare GLP-1 uptake as a bellwether for how broadly the drugs will penetrate the senior population and what fiscal pressure expanded access may eventually place on the federal health program.
Continue reading at Business News.
